Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr Danilov on the Importance of Using BTK as a Target in CLL Treatment

August 6th 2024

Alexey Danilov, MD, PhD, discusses the importance of using BTK as a target, as well as recent updates on BTK degraders within the CLL treatment paradigm.

Updates in CLL Treatment Strategies with Noncovalent BTKis

August 6th 2024

Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice.

Management Strategies for BTKi-Related CVAEs in CLL

August 6th 2024

Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.

Approach to Hypertension Management With BTKi Treatment

August 5th 2024

Medical experts deliberate on strategies for managing newly developed or exacerbated hypertension in patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia.

Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

August 5th 2024

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

BTK Degraders and Fixed-Duration Regimens May Represent the Future in CLL

August 2nd 2024

Alexey Danilov, MD, PhD, highlights the evolution of targeting BTK, sharing new data on BTK degraders and more in chronic lymphocytic leukemia

Minimal Residual Disease Status Displays Association with PFS in CLL

August 1st 2024

Minimal residual disease status was associated with progression-free survival in chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Future Treatment Directions and Ongoing Trials in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.

Real-World Safety Data for BTK Inhibitors in CLL from EHA 2024

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss real-world safety data for BTK inhibitors in chronic lymphocytic leukemia from EHA 2024.

Matching-Adjusted Indirect Comparisons of BTK Inhibitors in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss matching-adjusted indirect comparisons of BTK inhibitors in chronic lymphocytic leukemia.

The SEQUOIA Trial of Zanubrutinib vs BR in Previously Untreated CLL/SLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.

Translating BTK Inhibitor Data into Clinical Decision-Making

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Factors for Selecting a BTK Inhibitor vs Other Regimens in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Dr Opat on the Accessibility of Sonrotoclax Plus Zanubrutinib in R/R CLL/SLL

July 31st 2024

Stephen Opat, MBBS, discusses the accessibility of sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

July 30th 2024

The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.

Navigating 2L Treatment Options in CLL

July 30th 2024

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

Dr Opat on Sonrotoclax With Zanubrutinib in Relapsed/Refractory CLL and SLL

July 29th 2024

Stephen Opat, MBBS, discusses sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Fixed-Duration Acalabrutinib/Venetoclax Yields PFS Benefit vs SOC in Frontline CLL

July 29th 2024

Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab elicited favorable PFS outcomes in previously untreated chronic lymphocytic leukemia.

BTKi Intolerance in Real-world Practice & Management Strategy

July 29th 2024

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

How Experts View MAIC Data That was Presented at EHA 2024

July 29th 2024

A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.